Ab8 also does not bind to human cells, which scientists consider a good sign that it won’t have negative side-effects in people.
“Ab8 not only has potential as therapy for COVID-19, but it also could be used to keep people from getting SARS-CoV-2 infections,” said co-author, chief of the Division of Infectious Diseases at and Pitt.
“Antibodies of larger size have worked against other infectious diseases and have been well tolerated, giving us hope that it could be an effective treatment for patients with COVID-19 and for
protection of those who have never had the infection and are not immune.”
Ab8’s small size might allow it to be given as an inhaled drug or intradermally, rather than intravenously through an IV drip, like most monoclonal antibodies currently in development.